Biocon rallies intraday after getting approval for insulin Glargine in Mexico, but ends in red

NEW DELHI: Biocon Ltd rallied a little over 3 per cent in trade on Friday, after the biotechnology major said that it has received approval for its insulin Glargine from the Mexican health authority.

The company's insulin Glargine has been approved by Cofepris, the Mexican health authority, through its Mexican partner PiSA Farmaceutica (PiSA), PTI reported quoting Biocon statement.

Galactus by PiSA is the first insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, it added

Biocon currently has marketing approvals in over 60 countries for rh-Insulin and in over 20 countries for insulin Glargine, the company said.